BioCentury | Feb 4, 2013
Emerging Company Profile
Incanthera: Using, not targeting, MMP
...the clinic have been abandoned due to lack of specificity and resulting musculoskeletal side effects. Incanthera...
...selective for MMP14 and MMP15, and these are really only present at solid tumor sites," Incanthera...
...in preclinical testing to treat cancer. Kadmon licensed the compound from Dyax Corp. last year. Incanthera...
...selective for MMP14 and MMP15, and these are really only present at solid tumor sites," Incanthera...
...in preclinical testing to treat cancer. Kadmon licensed the compound from Dyax Corp. last year. Incanthera...
